HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Ching-Lung Lai Selected Research

Chronic Hepatitis B

9/2015Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities.
9/2015Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent.
4/2015Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study.
3/2015Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study.
6/2014Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B.
5/2014Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.
3/2014HLA-DP and γ-interferon receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection.
3/2014Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment.
1/2014Telbivudine improves renal function in patients with chronic hepatitis B.
1/2014Artificial neural network accurately predicts hepatitis B surface antigen seroclearance.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Ching-Lung Lai Research Topics

Disease

86Chronic Hepatitis B
09/2015 - 02/2002
70Hepatitis B
09/2015 - 07/2002
36Infection
09/2015 - 02/2002
27Fibrosis (Cirrhosis)
02/2015 - 03/2002
16Hepatocellular Carcinoma (Hepatoma)
10/2015 - 03/2002
10Hepatitis
11/2014 - 02/2002
6Liver Cirrhosis (Hepatic Cirrhosis)
02/2015 - 03/2008
6Liver Diseases (Liver Disease)
01/2014 - 12/2003
5Viremia
09/2015 - 02/2002
4Chronic Hepatitis C
09/2008 - 02/2002
4Neoplasms (Cancer)
07/2008 - 09/2002
3Disease Progression
09/2015 - 08/2004
3Chronic Hepatitis (Chronic Active Hepatitis)
12/2007 - 01/2006
2Liver Neoplasms (Liver Cancer)
10/2015 - 01/2013
2Muscular Diseases (Myopathy)
03/2014 - 09/2010
2HIV Infections (HIV Infection)
06/2013 - 03/2003
2Alcoholic Liver Diseases (Alcoholic Liver Disease)
08/2007 - 03/2003
2Biliary Liver Cirrhosis (Primary Biliary Cirrhosis)
08/2007 - 03/2003
2Cholangitis
10/2003 - 07/2002
1Hypertension (High Blood Pressure)
02/2015
1Hematologic Neoplasms (Hematological Malignancy)
11/2014
1Lymphoma (Lymphomas)
11/2014
1Hypophosphatemia
03/2014
1Lactic Acidosis
03/2014
1Kidney Diseases (Kidney Disease)
01/2014
1Gastritis
08/2013
1Inflammation
08/2013
1Peripheral Nervous System Diseases (PNS Diseases)
09/2010
1Substance-Related Disorders (Drug Abuse)
09/2010
1Hepatolenticular Degeneration (Wilson's Disease)
01/2008
1Abdominal Pain (Pain, Abdominal)
10/2004
1Hepatitis E
06/2004
1Cholestasis
02/2004
1Granuloma
02/2004
1Liver Failure
10/2003
1End Stage Liver Disease
10/2003
1Ascites
04/2003
1Hepatitis D
03/2003

Drug/Important Bio-Agent (IBA)

54AntigensIBA
04/2015 - 07/2002
51Hepatitis B e AntigensIBA
04/2015 - 07/2002
46DNA (Deoxyribonucleic Acid)IBA
03/2015 - 07/2002
36Lamivudine (3TC)FDA Link
06/2014 - 07/2002
27Hepatitis B Surface Antigens (HBsAg)FDA Link
09/2015 - 01/2003
19entecavirFDA Link
04/2015 - 12/2002
15Alanine Transaminase (SGPT)IBA
01/2012 - 07/2002
11telbivudineFDA Link
03/2014 - 09/2004
9InterferonsIBA
09/2015 - 07/2002
6adefovir dipivoxil (Hepsera)FDA Link
12/2007 - 12/2003
5hepatitis B hyperimmune globulinIBA
11/2014 - 02/2003
5BilirubinIBA
01/2011 - 03/2002
5alpha-Fetoproteins (AFP)IBA
01/2011 - 09/2002
4Ribavirin (Virazole)FDA LinkGeneric
12/2013 - 04/2003
4adefovirIBA
01/2013 - 12/2007
4Antiviral Agents (Antivirals)IBA
01/2011 - 02/2003
3nasIBA
03/2014 - 01/2007
3HLA-DP Antigens (HLA-DP)IBA
03/2014 - 01/2013
3tenofovirFDA Link
10/2013 - 01/2011
3Interferon-alpha (Interferon Alfa)FDA Link
01/2013 - 06/2003
3Immunoglobulins (Immunoglobulin)IBA
10/2011 - 04/2004
2Non-alcoholic Fatty Liver DiseaseIBA
02/2015 - 08/2007
2Creatine Kinase (Creatine Phosphokinase)IBA
03/2014 - 09/2010
2Messenger RNA (mRNA)IBA
08/2013 - 10/2006
2VaccinesIBA
10/2012 - 12/2008
2Aspartate Aminotransferases (Aspartate Transaminase)IBA
01/2012 - 03/2002
2ruberythric acid (AlP)IBA
01/2011 - 12/2008
2Carbon MonoxideIBA
01/2011 - 03/2003
2Biological Markers (Surrogate Marker)IBA
12/2008 - 08/2008
1Estrogens (Estrogen)FDA Link
10/2015
1Estradiol (Estrace)FDA LinkGeneric
10/2015
1Reverse Transcriptase InhibitorsIBA
09/2015
1N 30IBA
03/2015
1rituximab (Mabthera)FDA Link
11/2014
12'-fluoro-5-methylarabinosyluracil (Clevudine)IBA
03/2014
1HLA-DPA1 (HLA DPA1)IBA
03/2014
1CreatinineIBA
01/2014
1Cadherins (E-Cadherin)IBA
08/2013
1Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link
08/2013
1Interleukin-1 (Interleukin 1)IBA
08/2013
1Nitric Oxide (Nitrogen Monoxide)FDA Link
08/2013
1tenofovir disoproxil (Viread)FDA Link
06/2013
1HLA-DPB1 (HLA DPB1)IBA
01/2013
1Surface Antigens (Surface Antigen)IBA
01/2012
1GuanosineIBA
10/2011
1CopperIBA
01/2008
1Circular DNAIBA
10/2006
1lysyl- lysyl- leucyl- phenylalanyl- lysyl- lysyl- isoleucyl- leucyl- lysyl- tyrosyl- leucinamideIBA
10/2004
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
02/2004
1FibrinIBA
02/2004
1PlasticsIBA
10/2003

Therapy/Procedure

13Liver Transplantation
06/2015 - 01/2003
7Transplants (Transplant)
11/2014 - 02/2003
2Withholding Treatment
09/2015 - 04/2015
2Blood Transfusion (Blood Transfusions)
03/2011 - 09/2010
2Oral Administration
05/2009 - 03/2006
2Endoscopic Sphincterotomy
10/2003 - 07/2002
1Investigational Therapies (Experimental Therapy)
09/2015
1Drug Therapy (Chemotherapy)
11/2014
1Transplantation (Transplant Recipients)
06/2013
1Decompression
10/2003
1Stents
10/2003